NeoGenomics Inc

NEO

Company Profile

  • Business description

    NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.

  • Contact

    9490 NeoGenomics Way
    Fort MyersFL33912
    USA

    T: +1 239 768-0600

    E: [email protected]

    https://www.neogenomics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Diagnostics & Research

    Fiscal Year End

    31 December 2026

    Employees

    2,500

Stocks News & Analysis

stocks

Undervalued ASX healthcare provider

Solid demand profile for global leader.
stocks

SpaceX: What investors need to know about its enormous upcoming IPO

Morningstar launches research coverage of SpaceX.
stocks

Fair value lifts for toll road operator as Aussie fuel supply steadies

An Australian fuel shortage is becoming increasingly unlikely, a relief for ASX toll road operator.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,966.0017.100.19%
CAC 408,230.2283.631.03%
DAX 4025,266.55263.511.05%
Dow JONES (US)51,078.8846.420.09%
FTSE 10010,382.4643.510.42%
HKSE26,029.84631.662.49%
NASDAQ27,086.81114.190.42%
Nikkei 22566,734.24200.09-0.30%
NZX 50 Index13,170.7173.84-0.56%
S&P 5007,599.9619.900.26%
S&P/ASX 2008,724.4017.700.20%
SSE Composite Index4,075.1017.360.43%

Market Movers